Page last updated: 2024-08-25

zoledronic acid and Genetic Predisposition

zoledronic acid has been researched along with Genetic Predisposition in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cserepes, M; Dobos, J; Hegedűs, B; Horváth, O; Izsák, V; Kenessey, I; Kói, K; Molnár, D; Tímár, J; Tóvári, J1
Brandi, ML; Cavalli, L; Cavalli, T; Falchetti, A; Marini, F; Masi, L; Tonelli, P1
Arbitrio, M; Baudi, F; Calimeri, T; Cannataro, M; Cucinotto, I; Di Martino, MT; Guzzi, PH; Leone, E; Piro, E; Prantera, T; Rossi, M; Tagliaferri, P; Tassone, P; Veltri, P1
Bandeira, F; Colares, V; Griz, L1

Reviews

1 review(s) available for zoledronic acid and Genetic Predisposition

ArticleYear
[Treatment of Paget's disease of bone: importance of the zoledronic acid].
    Arquivos brasileiros de endocrinologia e metabologia, 2006, Volume: 50, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Diphosphonates; Female; Follow-Up Studies; Genetic Predisposition to Disease; Humans; Hypercalcemia; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteitis Deformans; Pamidronate; Remission Induction; Treatment Outcome; Zoledronic Acid

2006

Other Studies

3 other study(ies) available for zoledronic acid and Genetic Predisposition

ArticleYear
KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Oncotarget, 2016, 11-29, Volume: 7, Issue:48

    Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Movement; Cell Proliferation; Cisplatin; Diphosphonates; Dose-Response Relationship, Drug; Genetic Predisposition to Disease; Humans; Imidazoles; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, SCID; Mutation; Neoplasm Invasiveness; Neovascularization, Pathologic; Phenotype; Proto-Oncogene Proteins p21(ras); Signal Transduction; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays; Zoledronic Acid

2016
Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw.
    Frontiers in bioscience (Elite edition), 2011, 01-01, Volume: 3, Issue:1

    Topics: Bone Density Conservation Agents; Diphosphonates; Female; Gene Frequency; Genetic Predisposition to Disease; Geranyltranstransferase; Humans; Imidazoles; Italy; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Pharmacogenetics; Polymorphism, Single Nucleotide; Retrospective Studies; White People; Zoledronic Acid

2011
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling.
    British journal of haematology, 2011, Volume: 154, Issue:4

    Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Gene Frequency; Genetic Predisposition to Disease; Humans; Imidazoles; Jaw Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Polymorphism, Single Nucleotide; PPAR gamma; Zoledronic Acid

2011
chemdatabank.com